Cell & Gene Therapies

(Image: Getty/Rawpixel)

Hired and Retired: A summer of change

By Vassia Barba

As we have entered the summer, companies have taken to refreshing their leadership positions, including at companies such as Gilead, Alnylam, and Maze Therapeutics.

Five biggest CDMO deals of the year

Five deals reshaping the CDMO industry this year

By Ben Hargreaves

The major trend so far in 2019 is the willingness to deploy capital to expand services in the cell and gene therapy sector, and we outline the five most significant deals thus far.

(Image: Getty/vchal)

Catalent bolsters Paragon through Novavax deal

By Vassia Barba

Aiming to boost the gene therapy development and manufacturing capabilities of Paragon, which Catalent acquired in April, the CDMO has agreed to acquire all of the gene therapy-related assets from Novavax, a late-stage vaccine developer.

(Image: Getty/BrianAJackson)

Hired and Retired: The knock-on effect

By Ben Hargreaves & Maggie Lynch

BMS’ capture of Celgene caught much attention, due to the size and scale of the acqusition, but rival companies have taken the chance to snap up employees that have left after the deal.

(Image: Getty/Tuomas Lehitnen)

SGS’ Glasgow biosafety facility doubles in size

By Maggie Lynch

SGS’ completed the ₤8.7m expansion of its large molecule testing facility in Glasgow and made room to increase its existing biosafety service and PCR platform capabilities.